Pharmacological Alternatives to Psychostimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder

Popper, Charles W.

doi:10.1016/s1056-4993(18)30109-3

Cited by 82 publications

(51 citation statements)

References 269 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Psychostimulants are effective for hyperactivity (Biederman & Faraone, 2005), neuroleptics for aggression (Turgay, 2005), mood stabilizers for negative emotions in mood swings (Smith, Cornelius, Warnock, Bell & Young, 2007), and, possibly, anti-depressants for impulsivity (Popper, 1997). Psychotherapeutic and educative efforts may target behaviour patterns, deficient cognitive abilities and/or hampered personality maturation.…”

Section: Treatment Responsementioning

confidence: 99%

Continuity of aggressive antisocial behavior from childhood to adulthood: The question of phenotype definition

Hofvander

Ossowski

Lundström

et al. 2009

International Journal of Law and Psychiatry

View full text Add to dashboard Cite

Section: Treatment Responsementioning

confidence: 99%

Continuity of aggressive antisocial behavior from childhood to adulthood: The question of phenotype definition

Hofvander

Ossowski

Lundström

et al. 2009

International Journal of Law and Psychiatry

View full text Add to dashboard Cite

“…A primeira opção será a do estimulante, seja sob forma habitual ou forma de ação prolongada, sempre que o TDAH predominar com desatenção 44,45 . A indicação primária de outras substâncias poderá ocorrer em função da existência de co-morbidade e outros diagnósticos associados [46][47][48][49] . É de fundamental importância que o médico responsável pela indicação da medicação esteja afeito ao uso da mesma, para que a família encontre segurança e haja adesão ao tratamento.…”

Section: Tratamentounclassified

Avaliação e manejo da criança com dificuldade escolar e distúrbio de atenção

Araújo¹

2002

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

ResumoObjetivo: esta revisão tem como objetivo oferecer aos pediatras noções atualizadas das principais causas encontradas em crianças com dificuldade escolar, com enfoque mais detalhado na avaliação e na conduta dos casos associados ao transtorno de déficit de atenção.Fontes dos dados: este artigo baseou-se em uma revisão sistemática da literatura médica a partir de levantamento de artigos indexados no Medline, através da busca pelo PubMed, nos últimos cinco anos, com as palavras chave de transtorno do aprendizado, déficit de atenção, dislexia (transtorno de leitura) e discalculia (transtorno de matemática). Foram incluídos os artigos com enfoque na avaliação e conduta. Incluem-se dados estatísticos do Datasus sobre alfabetização e escolaridade, e dados do sistema de avaliação do ensino básico do MEC.Síntese dos dados: observa-se uma escassez de dados estatísti-cos sobre causas médicas de baixo desempenho escolar no Brasil. A deficiência auditiva, visual e mental, além do transtorno de déficit de atenção (TDAH) e dos transtornos específicos do aprendizado, devem fazer parte do diagnóstico diferencial nestes casos. A importância do acompanhamento do desenvolvimento até a idade escolar em crianças com fatores de risco para o baixo desempenho escolar é fundamental. Conclusões:O tratamento medicamentoso com estimulantes, antidepressivos ou clonidina, associado ao acompanhamento multidisciplinar, concorre para o melhor desempenho das crianças com TDAH na escola. J Pediatr (Rio J) 2002; 78 (Supl.1): S104-S110: TDAH, dificuldade de desenvolvimento da leitura, aprendizado, diagnóstico, tratamento. AbstractObjective: this review aims at providing pediatricians with an update on the main causes involved in low school achievement. A more detailed approach is given for the management and treatment of attention deficit hyperactive disorder.Sources: data was obtained by a systematic review of published literature in Medline, through a search on Pubmed in the last five years. The key words used were learning disability, attention deficit, dyslexia (reading disorder) and dyscalculia (mathematical disorder). Studies focusing evaluation and management were retrieved. Governmental population educational data on literacy was also included.Summary of the findings: statistical medical Brazilian data on the subject is scarce. Hearing, visual and mental deficiency, together with attention deficit hyperactive disorder and specific learning disorders should be part of the differential diagnosis of children with poor school achievement. Development should be carefully followed until school entrance particularly in children at risk.Conclusions: therapy with stimulants, anti-depressive drugs or cloninidine with multimodal treatment improves school achievement in children with attention deficit hyperactive disorder.J Pediatr (Rio J) 2002; 78 (Supl.1): S104-S110: attention deficit disorder with hyperactivity, dyslexia, learning disorders, diagnosis, treatment.

show abstract

“…Although the most effective treatments for ADHD are based on the administration of stimulant drugs, there is evidence that some serotonin agonists, including selective serotonin reuptake inhibitors, tricyclic antidepressants and monoamine oxidase inhibitors, also reduce ADHD symptoms. [23][24][25][26] Moreover, pharmacological studies in humans and rodents support a contribution of the serotoninergic system to psychostimulant-mediated behavior, such as locomotor stimulatory and rewarding effects. [27][28][29][30][31][32][33] Animal models emphasize the potential importance of serotonin in ADHD too.…”

Section: Introductionmentioning

confidence: 99%

Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB

et al. 2007

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder in which different genetic and environmental susceptibility factors are involved. Several lines of evidence support the view that at least 30% of ADHD patients diagnosed in childhood continue to suffer the disorder during adulthood and that genetic risk factors may play an essential role in the persistence of the disorder throughout lifespan. Genetic, biochemical and pharmacological studies support the idea that the serotonin system participates in the etiology of ADHD. Based on these data, we aimed to analyze single nucleotide polymorphisms across 19 genes involved in the serotoninergic neurotransmission in a clinical sample of 451 ADHD patients (188 adults and 263 children) and 400 controls using a population-based association study. Several significant associations were found after correcting for multiple testing: (1) the DDC gene was strongly associated with both adulthood (P = 0.00053; odds ratio (OR) = 2.17) and childhood ADHD (P = 0.0017; OR = 1.90); (2) the MAOB gene was found specifically associated in the adult ADHD sample (P = 0.0029; OR = 1.90) and (3) the 5HT2A gene showed evidence of association only with the combined ADHD subtype both in adults (P = 0.0036; OR = 1.63) and children (P = 0.0084; OR = 1.49). Our data support the contribution of the serotoninergic system in the genetic predisposition to ADHD, identifying common childhood and adulthood ADHD susceptibility factors, associations that are specific to ADHD subtypes and one variant potentially involved in the continuity of the disorder throughout lifespan.

show abstract

Pharmacological Alternatives to Psychostimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder

Cited by 82 publications

References 269 publications

Continuity of aggressive antisocial behavior from childhood to adulthood: The question of phenotype definition

Continuity of aggressive antisocial behavior from childhood to adulthood: The question of phenotype definition

Avaliação e manejo da criança com dificuldade escolar e distúrbio de atenção

Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB

Contact Info

Product

Resources

About